Nilotinib
Especificaciones
641571-10-0Número CAS
700-544-5Número CE
4-methyl-N-[3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]benzamideNombre IUPAC
C28H22F3N7OFórmula química
529.5 g/molPeso molecular
Nilotinib; 641571-10-0; AMN 107; AMN-107; nilotinibum; 4-Methyl-3-((4-(3-pyridinyl)-2-pyrimidinyl)amino)-N-(5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl)benzamide; Danziten; NSC-747599; 4-methyl-N-[3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]benzamide; DTXSID5042663; F41401512X; CHEBI:52172; 4-Methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide; 4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-N-[5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl]benzamide; Benzamide, 4-methyl-N-((3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-(4-(3-pyridinyl)-2-pyrimidinyl)amino)-; RefChem:58968; AMN 107 Base; DTXCID3022663; L01XE08; benzamide, 4-methyl-N-(3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-(3-pyridinyl)-2-pyrimidinyl)amino)-, hydrochloride, hydrate; Tasigna; AMN107; Nilotinib (AMN-107); Nilotinib free base; MFCD09833716; C28H22F3N7O; 4-Methyl-N-(3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)benzamide; 4-methyl-N-[3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-{[4-(pyridin-3-yl)pyrimidin-2-yl]amino}benzamide; 4-methyl-N-[3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]benzamide; CHEMBL255863; NSC747599; 4-Methyl-N-(3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-(4-(pyridin-3-yl)pyrimidin-2-ylamino)benzamide; benzamide, 4-methyl-N-[3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-; 4-methyl-N-(3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-{(4-(pyridin-3-yl)pyrimidin-2-yl)amino}benzamide; 4-Methyl-N-[3-(4-methyl-1-imidazolyl)-5-(trifluoromethyl)phenyl]-3-[[4-(3-pyridyl)-2-pyrimidyl]amino]benzamide; 4-Methyl-N-[3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]benzamide; Nilotinib,AMN107,Tasigna;4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide; SMR002544680; Nilotinib [USAN]; Nilotinib [USAN:INN:BAN]; Nilotinib?; HSDB 7842; UNII-F41401512X; 641571-10-0 (free base); Nilotinib (Standard); 3gp0; NILOTINIB [INN]; NILOTINIB [MI]; Nilotinib (USAN/INN); NILOTINIB [HSDB]; 1353151-22-0; NILOTINIB [VANDF]; NILOTINIB [MART.]; EC 700-544-5; NILOTINIB [USP-RS]; NILOTINIB [WHO-DD]; SCHEMBL7901; NILOTINIB [EMA EPAR]; MLS003915611; MLS006010160; Nilotinib - Bio-X trade mark; GTPL5697; orb1224371; orb1308331; orb3141255; SCHEMBL29366964; SCHEMBL29580067; GLXC-90226; HMS3244A13; HMS3244A14; HMS3244B13; HMS3295A23; HMS3654M07; HMS3748E11; HMS5079M05; EX-A8380; TAC35617; AC-647; BDBM50237710; EBC-11364; HY-10159R; MSK159953; NSC800804; s1033; AKOS005063561; CCG-264784; CS-0102; DB04868; FM10831; NSC 747599; NSC-800804; SB17315; SDCCGSBI-0634418.P004; NCGC00183285-01; NCGC00183285-03; NCGC00183285-04; NCGC00183285-09; NCGC00183285-12; NCGC00183285-15; 4-Methyl-3-(4-(3-pyridinyl)-2-pyrimidinyl)amino)-N-[5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl]benzamide; 4-Methyl-N-(3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)-phenyl)-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)benzamide; 4-methyl-N-[3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-benzamide; 4-methyl-N-[3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[[4-(3-pyridyl)pyrimidin-2-yl]amino]benzamide; AS-16214; BN164654; HY-10159; N-(3-(3-(1H-Imidazolyl)propoxy)phenyl)-4-methyl-3-((4-(3-pyridinyl)-2-pyrimidinyl)amino)benzamide; SY024415; N3346; NS00000665; SW218083-2; T1524; D08953; N-8207; AB01273978-01; AB01273978-02; AB01273978_03; EN300-7381984; F079266; Q412327; SR-01000931150; SR-01000931150-2; BRD-K81528515-001-04-7; BRD-K81528515-001-13-8; Z1741976994; 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide; 4-methyl-N-[3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[(4 -pyridin-3-ylpyrimidin-2-yl)amino]benzamide; 4-methyl-N-[3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino] benzamide; Benzamide, 4-methyl-N-(3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-(4-(3-pyridinyl)-2-pyrimidinyl)amino)-; Benzamide, 4-methyl-N-[3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]- (9CI)Sinónimos
Productos que contienen Nilotinib
NILOTINIB ACCORD 50 MG CAPSULAS DURAS EFGNILOTINIB ACCORD 200 MG CAPSULAS DURAS EFGNILOTINIB ACCORD 150 MG CAPSULAS DURAS EFGTASIGNA 200 MG CAPSULAS DURASTASIGNA 150 MG CAPSULAS DURASNILOTINIB ZENTIVA 200 MG CAPSULAS DURAS EFGNILOTINIB ZENTIVA 150 MG CAPSULAS DURAS EFGNILOTINIB ZENTIVA 200 mg, géluleNILOTINIB ZENTIVA 150 mg, géluleNILOTINIB ACCORD 200 mg, géluleNILOTINIB ACCORD 150 mg, géluleTasigna 200mg
Página 1 de 3
Empresas que venden Nilotinib
SL
Suzhou Lixin Pharmaceutical Co., LtdChinaSI
Sinoway Industrial Co.Ltd.ChinaSQ
SICHUAN QINGMU PHARMACEUTICAL CO.,LTD.ChinaSX
Sichuan Xieli Pharmaceutical Co., Ltd.ChinaAH
Accord Healthcare S.L.U.SpainNE
Novartis Europharm LimitedSpainPágina 1 de 2